BioCentury | Apr 8, 2002
Clinical News

Smart Anti-L-Selectin antibody: PDLI partner Scil Biomedicals GmbH (Martinsried, Germany) completed enrollment of 21 patients with moderate-to-severe plaque pso

...of neutrophils to endothelial cells Indication: Treat psoriasis Endpoint: Safety, tolerability, pharmacokinetics Status: PDLI partner Scil Biomedicals GmbH...
BioCentury | Mar 4, 2002
Company News

Scil Biomedicals management update

Scil Biomedicals GmbH, Martinsried, Germany Business: Biomaterial/Skin/Wound Promoted: Thomas Keller to CEO from VP of marketing and sales; he replaces Ulrich Martin, who departed WIR Staff Dermatology...
BioCentury | Jan 7, 2002
Company News

Scil Biomedicals management update

Scil Biomedicals GmbH, Martinsried, Germany Business: Biomaterial/Skin/Wound Hired: Andreas Schuetz as VP of pharmaceutical technology, formerly senior project manager at Vetter Pharma WIR Staff...
BioCentury | Nov 12, 2001
Clinical News

Smart Anti-L-Selectin antibody: Began Phase Ib trial

...of neutrophils to endothelial cells Indication: Treat psoriasis Endpoint: Safety, tolerability, pharmacokinetics Status: PDLI partner Scil Biomedicals GmbH...
BioCentury | Apr 23, 2001
Company News

Biopharm, Scil Biomedicals deal

...superfamily. SCIL will have rights to market the jointly-owned product worldwide. Biopharm GmbH, Heidelberg, Germany Scil Biomedicals GmbH...
BioCentury | Jan 10, 2000
Company News

Medarex, Scil Biomedicals deal

...$17 million in exchange for co-promotion rights in the U.S. Medarex Inc. (MEDX), Princeton, N.J. Scil Biomedicals GmbH...
BioCentury | Jan 10, 2000
Strategy

Medarex "Scils" a deal

...is required. Medarex Inc. , which last week partnered its MDX-RA and MDX-210 antibodies with Scil Biomedicals GmbH...
...acquisition by F. Hoffmann-La Roche . The president of Scil Technology Holding, the parent of Scil Biomedicals...
Items per page:
1 - 7 of 7
BioCentury | Apr 8, 2002
Clinical News

Smart Anti-L-Selectin antibody: PDLI partner Scil Biomedicals GmbH (Martinsried, Germany) completed enrollment of 21 patients with moderate-to-severe plaque pso

...of neutrophils to endothelial cells Indication: Treat psoriasis Endpoint: Safety, tolerability, pharmacokinetics Status: PDLI partner Scil Biomedicals GmbH...
BioCentury | Mar 4, 2002
Company News

Scil Biomedicals management update

Scil Biomedicals GmbH, Martinsried, Germany Business: Biomaterial/Skin/Wound Promoted: Thomas Keller to CEO from VP of marketing and sales; he replaces Ulrich Martin, who departed WIR Staff Dermatology...
BioCentury | Jan 7, 2002
Company News

Scil Biomedicals management update

Scil Biomedicals GmbH, Martinsried, Germany Business: Biomaterial/Skin/Wound Hired: Andreas Schuetz as VP of pharmaceutical technology, formerly senior project manager at Vetter Pharma WIR Staff...
BioCentury | Nov 12, 2001
Clinical News

Smart Anti-L-Selectin antibody: Began Phase Ib trial

...of neutrophils to endothelial cells Indication: Treat psoriasis Endpoint: Safety, tolerability, pharmacokinetics Status: PDLI partner Scil Biomedicals GmbH...
BioCentury | Apr 23, 2001
Company News

Biopharm, Scil Biomedicals deal

...superfamily. SCIL will have rights to market the jointly-owned product worldwide. Biopharm GmbH, Heidelberg, Germany Scil Biomedicals GmbH...
BioCentury | Jan 10, 2000
Company News

Medarex, Scil Biomedicals deal

...$17 million in exchange for co-promotion rights in the U.S. Medarex Inc. (MEDX), Princeton, N.J. Scil Biomedicals GmbH...
BioCentury | Jan 10, 2000
Strategy

Medarex "Scils" a deal

...is required. Medarex Inc. , which last week partnered its MDX-RA and MDX-210 antibodies with Scil Biomedicals GmbH...
...acquisition by F. Hoffmann-La Roche . The president of Scil Technology Holding, the parent of Scil Biomedicals...
Items per page:
1 - 7 of 7